Person: Shimon Sakaguchi
Asia Leaders
Shimon Sakaguchi Extended Treg Science Into Cancer and Heart Failure. Translation Must Now Prove Its Range
Shimon Sakaguchi’s 2026 research links Treg biology to checkpoint response and heart-failure fibrosis. Platform value will depend on reproducibility, manufacturing and patient selection.
Asia Leaders
Shimon Sakaguchi’s Nobel Prize Has Become a Clinical Manufacturing Test
Shimon Sakaguchi’s discoveries gave immunology a new control system. RegCell’s planned US and Japanese trials will test whether that science can become a scalable autoimmune therapy rather than another elegant but expensive cell-therapy proposition.